- Pertuzumab, sold
under the
brand name
Perjeta, is a
monoclonal antibody used in
combination with
trastuzumab and
docetaxel for the
treatment of metastatic...
-
signaling pathway. This is the
first approved therapy for
advanced BCC. 2012:
Perjeta (pertuzumab): For use in
combination with
Herceptin (trastuzumab) and docetaxel...
-
published the
first studies with an
antibody called 2C4 (pertuzumab or
Perjeta),
targeting the Her-2
molecule in
breast and
other cancers. This was the...
- Peginterferon/alfa-2a|Pegasys]], (peginterferon alfa-2a) for
hepatitis B and C.
Perjeta (pertuzumab), for HER-2
positive breast cancer.
Polatuzumab vedotin|Polivy...
-
docetaxel (Taxotere), carboplatin,
trastuzumab (Herceptin),
pertuzumab (
Perjeta)
breast cancer with
positive HER2/neu
receptor Thal/Dex thalidomide, dexamethasone...
-
intravenous humanized PD-1
Metastatic melanoma 125514 Link
pertuzumab Perjeta Genentech 6/8/2012
intravenous humanized HER2
Metastatic breast cancer...
-
mouse MUC1
cancer Perakizumab mab
humanized IL-17A
arthritis Pertuzumab Perjeta mab
humanized HER2/neu Y
cancer Pexelizumab scFv
humanized C5 reduction...
- 29 June 2020. "FDA
approves Roche's
Phesgo (fixed-dose
combination of
Perjeta and
Herceptin for
subcutaneous injection) for HER2-positive
breast cancer"...
- and the
creation of the
drugs trastuzumab (Herceptin) and
pertuzumab (
Perjeta). In 1995,
after finishing his residency,
Drebin became an ****istant Professor...
- 2016.
Andrew Pollack (September 28, 2014). "Roche
Breast Cancer Drug
Perjeta Appears to
Greatly Extend Patients' Lives". The New York Times. Retrieved...
